Sinphar Tian-Li

Sinphar Tian-Li is a specialized pharmaceutical subsidiary of the Sinphar Group, focused on the research, development, and modernization of botanical medicines. The company is globally recognized for its expertise in Cistanche tubulosa extraction and the development of standardized botanical drugs for neurodegenerative diseases. Its lead clinical program, TLE102 (Memoregain), is a purified botanical extract targeting Alzheimer's disease and vascular dementia, which has reached Phase 3 clinical trials in several jurisdictions. Operating out of Hangzhou, China, Sinphar Tian-Li maintains large-scale GMP manufacturing facilities that support both its pharmaceutical pipeline and its commercial health supplement business. The company integrates traditional herbal knowledge with rigorous modern clinical validation to address unmet needs in cognitive health.